{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:42:39Z","timestamp":1788302559923,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T00:00:00Z","timestamp":1559520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T00:00:00Z","timestamp":1559520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Collaboration for Leadership in Applied Health Research and Care - East Midlands"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The clinical benefit of aspirin for the primary prevention of cardiovascular disease (CVD) in diabetes remains uncertain. To evaluate the efficacy and safety of aspirin for the primary prevention of cardiovascular outcomes and all-cause mortality events in people with diabetes, we conducted an updated meta-analysis of published randomised controlled trials (RCTs) and a pooled analysis of individual participant data (IPD) from three trials.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Randomised controlled trials of aspirin compared with placebo (or no treatment) in participants with diabetes with no known CVD were identified from MEDLINE, Embase, Cochrane Library, and manual search of bibliographies to January 2019. Relative risks with 95% confidence intervals were used as the summary measures of associations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 12 RCTs based on 34,227 participants with a median treatment duration of 5.0\u00a0years. Comparing aspirin use with no aspirin, there was a significant reduction in risk of major adverse cardiovascular events (MACE)0.89 (0.83\u20130.95), with a number needed to treat (NNT)of 95 (95% CI 61 to 208) to prevent one MACE over 5\u00a0years average follow-up. Evidence was lacking of heterogeneity and publication bias among contributing trials for MACE. Aspirin use had no effect on other endpoints including all-cause mortality; however, there was a significant reduction in stroke for aspirin dosage\u2009\u2264\u2009100\u00a0mg\/day 0.75 (0.59\u20130.95). There were no significant effects of aspirin use on major bleeding and other bleeding events, though some of the estimates were imprecise. Pooled IPD from the three trials (2306 participants) showed no significant evidence of an effect of aspirin on any of the outcomes evaluated; however, aspirin reduced the risk of MACE in non-smokers 0.70 (0.51\u20130.96) with a NNT of 33 (95% CI 20 to 246) to prevent one MACE.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Aspirin has potential benefits in cardiovascular primary prevention in diabetes. The use of low dose aspirin may need to be individualised and based on each individual\u2019s baseline CVD and bleeding risk.<\/jats:p>\n                <jats:p><jats:italic>Systematic review registration<\/jats:italic> PROSPERO: CRD42019122326<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-019-0875-4","type":"journal-article","created":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T16:02:52Z","timestamp":1559577772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8335-7018","authenticated-orcid":false,"given":"Samuel","family":"Seidu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setor K.","family":"Kunutsor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard D.","family":"Sesso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Gaziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. E.","family":"Buring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carla","family":"Roncaglioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Khunti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,3]]},"reference":[{"issue":"2","key":"875_CR1","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1464-5491.2008.02640.x","volume":"26","author":"U Bulugahapitiya","year":"2009","unstructured":"Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med. 2009;26(2):142\u20138.","journal-title":"Diabet Med"},{"issue":"7329","key":"875_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"C Antithrombotic Trialists","year":"2002","unstructured":"Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71\u201386.","journal-title":"BMJ"},{"issue":"9678","key":"875_CR3","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","volume":"373","author":"C Antithrombotic Trialists","year":"2009","unstructured":"Antithrombotic Trialists C, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849\u201360.","journal-title":"Lancet"},{"key":"875_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1475-2840-10-25","volume":"10","author":"S Butalia","year":"2011","unstructured":"Butalia S, Leung AA, Ghali WA, Rabi DM. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Diabetol. 2011;10:25.","journal-title":"Cardiovasc Diabetol"},{"issue":"25","key":"875_CR5","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1016\/j.jacc.2010.04.003","volume":"55","author":"M Pignone","year":"2010","unstructured":"Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol. 2010;55(25):2878\u201386.","journal-title":"J Am Coll Cardiol"},{"key":"875_CR6","doi-asserted-by":"publisher","first-page":"b4531","DOI":"10.1136\/bmj.b4531","volume":"339","author":"G De Berardis","year":"2009","unstructured":"De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, Nicolucci A. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ. 2009;339:b4531.","journal-title":"BMJ"},{"issue":"2","key":"875_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.diabres.2009.09.029","volume":"87","author":"C Zhang","year":"2010","unstructured":"Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M, Wang K, Zou Y, Ge J. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2010;87(2):211\u20138.","journal-title":"Diabetes Res Clin Pract"},{"issue":"39","key":"875_CR8","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"L Ryden","year":"2013","unstructured":"Authors\/Task Force M, Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34(39):3035\u201387.","journal-title":"Eur Heart J"},{"issue":"3","key":"875_CR9","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/dme.13133","volume":"34","author":"SK Kunutsor","year":"2017","unstructured":"Kunutsor SK, Seidu S, Khunti K. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. Diabet Med. 2017;34(3):316\u201327.","journal-title":"Diabet Med"},{"issue":"16","key":"875_CR10","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","volume":"379","author":"L Bowman","year":"2018","unstructured":"Group ASC, Bowman L, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529\u201339.","journal-title":"N Engl J Med"},{"issue":"10152","key":"875_CR11","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","volume":"392","author":"JM Gaziano","year":"2018","unstructured":"Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, Howard G, Pearson TA, Rothwell PM, Ruilope LM, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036\u201346.","journal-title":"Lancet"},{"issue":"16","key":"875_CR12","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","volume":"379","author":"JJ McNeil","year":"2018","unstructured":"McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, Reid CM, Lockery JE, Kirpach B, Storey E, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379(16):1509\u201318.","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"875_CR13","first-page":"S4","volume":"38","author":"American Diabetes Association","year":"2015","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20132015: summary of revisions. Diabetes Care. 2015;38(Suppl):S4.","journal-title":"Diabetes Care"},{"issue":"7","key":"875_CR14","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"issue":"16","key":"875_CR15","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1001\/jama.2015.3656","volume":"313","author":"LA Stewart","year":"2015","unstructured":"Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF. Group P-ID: preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement. JAMA. 2015;313(16):1657\u201365.","journal-title":"JAMA"},{"key":"875_CR16","unstructured":"Cochrane Collaboration Individual Patient Data Meta-analysis Methods Group. FAQs (Frequently Asked Questions) on IPD meta-analysis. http:\/\/www.ctu.mrc.ac.uk\/cochrane\/ipdmg\/faq.asp#faq26."},{"key":"875_CR17","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1136\/bmj.c221","volume":"340","author":"RD Riley","year":"2010","unstructured":"Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010;340:521\u20135.","journal-title":"BMJ"},{"key":"875_CR18","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"6","key":"875_CR19","first-page":"1269","volume":"11","author":"J Cornfield","year":"1951","unstructured":"Cornfield J. A method of estimating comparative rates from clinical data; applications to cancer of the lung, breast, and cervix. J Natl Cancer Inst. 1951;11(6):1269\u201375.","journal-title":"J Natl Cancer Inst"},{"issue":"7414","key":"875_CR20","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"7109","key":"875_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"6618","key":"875_CR22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1136\/bmj.296.6618.313","volume":"296","author":"R Peto","year":"1988","unstructured":"Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed). 1988;296(6618):313\u20136.","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"3","key":"875_CR23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJM198907203210301","volume":"321","author":"Steering Committee of the Physicians\u2019 Health Study Research Group","year":"1989","unstructured":"Steering Committee of the Physicians\u2019 Health Study Research Group. Final report on the aspirin component of the ongoing Physicians\u2019 Health Study. Steering Committee of the Physicians\u2019 Health Study Research Group. N Engl J Med. 1989;321(3):129\u201335.","journal-title":"N Engl J Med"},{"issue":"10","key":"875_CR24","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1001\/jama.1992.03490100090033","volume":"268","author":"A Kassoff","year":"1992","unstructured":"Kassoff A, Buzney SM, McMeel JW, Weiter JJ, Doyle GJ, Immerman RL, Friedman GR, Klein ML, Dreyer R, Chenoweth R, Handelman I. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 14, ETDRS Investigators. JAMA. 1992;268(10):1292\u2013300.","journal-title":"JAMA"},{"issue":"9098","key":"875_CR25","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","volume":"351","author":"Medical Research Council\u2019s General Practice Research Framework","year":"1998","unstructured":"Medical Research Council\u2019s General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 1998;351(9098):233\u201341.","journal-title":"Lancet"},{"issue":"9118","key":"875_CR26","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial, HOT Study Group. Lancet. 1998;351(9118):1755\u201362.","journal-title":"Lancet"},{"issue":"12","key":"875_CR27","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.2337\/diacare.26.12.3264","volume":"26","author":"M Sacco","year":"2003","unstructured":"Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A, Group PPPC. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care. 2003;26(12):3264\u201372.","journal-title":"Diabetes Care"},{"issue":"13","key":"875_CR28","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa050613","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293\u2013304.","journal-title":"N Engl J Med"},{"key":"875_CR29","doi-asserted-by":"publisher","first-page":"a1840","DOI":"10.1136\/bmj.a1840","volume":"337","author":"J Belch","year":"2008","unstructured":"Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.","journal-title":"BMJ"},{"issue":"18","key":"875_CR30","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1001\/jama.2008.623","volume":"300","author":"H Ogawa","year":"2008","unstructured":"Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y. Japanese primary prevention of atherosclerosis with aspirin for diabetes. Trial I: low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300(18):2134\u201341.","journal-title":"JAMA."},{"issue":"23","key":"875_CR31","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1001\/jama.2014.15690","volume":"312","author":"Y Ikeda","year":"2014","unstructured":"Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, Sugawara M, Ando K, Murata M, Yokoyama K, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60\u00a0years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014;312(23):2510\u201320.","journal-title":"JAMA"},{"issue":"5","key":"875_CR32","doi-asserted-by":"publisher","first-page":"e0126767","DOI":"10.1371\/journal.pone.0126767","volume":"10","author":"SB Larsen","year":"2015","unstructured":"Larsen SB, Grove EL, Neergaard-Petersen S, Wurtz M, Hvas AM, Kristensen SD. Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease. PLoS ONE. 2015;10(5):e0126767.","journal-title":"PLoS ONE"},{"issue":"10","key":"875_CR33","first-page":"1569","volume":"124","author":"WJ Li","year":"2011","unstructured":"Li WJ, Zhang HY, Miao CL, Tang RB, Du X, Shi JH, Ma CS. Cigarette smoking inhibits the anti-platelet activity of aspirin in patients with coronary heart disease. Chin Med J (Engl). 2011;124(10):1569\u201372.","journal-title":"Chin Med J (Engl)"},{"issue":"15","key":"875_CR34","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1001\/archinte.167.15.1593","volume":"167","author":"JD Snoep","year":"2007","unstructured":"Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med. 2007;167(15):1593\u20139.","journal-title":"Arch Intern Med"},{"issue":"7637","key":"875_CR35","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1136\/bmj.39430.529549.BE","volume":"336","author":"G Krasopoulos","year":"2008","unstructured":"Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin \u201cresistance\u201d and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336(7637):195\u20138.","journal-title":"BMJ"},{"issue":"3","key":"875_CR36","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1001\/jama.2018.20578","volume":"321","author":"SL Zheng","year":"2019","unstructured":"Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA. 2019;321(3):277\u201387.","journal-title":"JAMA"},{"key":"875_CR37","doi-asserted-by":"publisher","DOI":"10.1177\/2047487319826439","author":"F Fortuni","year":"2019","unstructured":"Fortuni F, Crimi G, Gritti V, Mirizzi AM, Leonardi S, Ferrari GM. Primum non nocere: an updated meta-analysis on aspirin use in primary prevention of cardiovascular disease in patients with diabetes. Eur J Prev Cardiol. 2019. https:\/\/doi.org\/10.1177\/2047487319826439.","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"875_CR38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.amjmed.2007.10.002","volume":"121","author":"JS Berger","year":"2008","unstructured":"Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med. 2008;121(1):43\u20139.","journal-title":"Am J Med"},{"issue":"7270","key":"875_CR39","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1136\/bmj.321.7270.1183","volume":"321","author":"S Derry","year":"2000","unstructured":"Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321(7270):1183\u20137.","journal-title":"BMJ"},{"issue":"22","key":"875_CR40","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1056\/NEJMra052717","volume":"353","author":"C Patrono","year":"2005","unstructured":"Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22):2373\u201383.","journal-title":"N Engl J Med"},{"key":"875_CR41","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1741-7015-4-22","volume":"4","author":"S Hernandez-Diaz","year":"2006","unstructured":"Hernandez-Diaz S, Garcia Rodriguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med. 2006;4:22.","journal-title":"BMC Med"},{"issue":"2","key":"875_CR42","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1055\/s-0038-1675380","volume":"45","author":"G Lippi","year":"2019","unstructured":"Lippi G, Danese E, Favaloro EJ. Harms and benefits of using aspirin for primary prevention of cardiovascular disease: a narrative overview. Semin Thromb Hemost. 2019;45(2):157\u201363.","journal-title":"Semin Thromb Hemost"},{"key":"875_CR43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1741-7015-5-29","volume":"5","author":"T Yerman","year":"2007","unstructured":"Yerman T, Gan WQ, Sin DD. The influence of gender on the effects of aspirin in preventing myocardial infarction. BMC Med. 2007;5:29.","journal-title":"BMC Med"},{"issue":"3","key":"875_CR44","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0002-9149(01)01631-9","volume":"88","author":"PA Gum","year":"2001","unstructured":"Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88(3):230\u20135.","journal-title":"Am J Cardiol"},{"issue":"1","key":"875_CR45","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12933-017-0550-6","volume":"16","author":"I Russo","year":"2017","unstructured":"Russo I, Penna C, Musso T, Popara J, Alloatti G, Cavalot F, Pagliaro P. Platelets, diabetes and myocardial ischemia\/reperfusion injury. Cardiovasc Diabetol. 2017;16(1):71.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"875_CR46","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.diabet.2017.11.002","volume":"44","author":"M Leggio","year":"2018","unstructured":"Leggio M, Bendini MG, Caldarone E, Lombardi M, Severi P, D\u2019Emidio S, Stavri DC, Armeni M, Bravi V, Mazza A. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: benefit or risk? Diabetes Metab. 2018;44(3):217\u201325.","journal-title":"Diabetes Metab"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0875-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-019-0875-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0875-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T16:12:48Z","timestamp":1628611968000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-019-0875-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,3]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["875"],"URL":"https:\/\/doi.org\/10.1186\/s12933-019-0875-4","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,3]]},"assertion":[{"value":"20 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}